UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): July 31, 2025 |
RxSight, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-40690 |
94-3268801 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
100 Columbia |
|
Aliso Viejo, California |
|
92656 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (949) 521-7830 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share |
|
RXST |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
This Amendment No. 1 to Current Report on Form 8-K/A (the “Amendment”) amends the Current Report on Form 8-K of RxSight, Inc. (the “Company”) dated July 31, 2025 and filed with the Securities and Exchange Commission on August 4, 2025 (the “Original Form 8-K”), which disclosed the appointment of Raymond W. Cohen to the Board of Directors of the Company (the “Board”), effective July 31, 2025. At the time of filing the Original Form 8-K, no determination had been made with respect to the appointment of Mr. Cohen to any committees of the Board.
This Amendment is being filed solely to report that on August 14, 2025, the Board, including each member of the Corporate Governance and Nominating Committee of the Board, appointed Mr. Cohen to the Compensation Committee of the Board (the “Compensation Committee”) and the Audit Committee of the Board (the “Audit Committee”), effective immediately. Effective upon such appointment to the Compensation Committee, the members of the Compensation Committee are Robert J. Palmisano (Chair), J. Andy Corley, Robert Warner, and Raymond W. Cohen. Effective upon such appointment to the Audit Committee, the members of the Audit Committee are Julie B. Andrews (Chair), Juliet Tammenoms Bakker, Tamara R. Fountain, M.D, and Raymond W. Cohen.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
RxSight, Inc. |
|
|
|
|
Date: |
August 15, 2025 |
By: |
/s/ Shelley Thunen |
|
|
|
Name: Shelley Thunen
Title: Co-President and Chief Financial Officer |
